Roquefort Therapeutics PLC (LSE:ROQ) said it has amended its exclusive licensing agreement with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc. relating to its AO-252 programme, extending the long stop date to 16 March 2026. The revision follows continued progress in the ongoing Phase I clinical study.
The trial has been broadened to cover patients with all solid tumours, while placing particular emphasis on prostate cancer. Management said this prioritisation is underpinned by encouraging pre-clinical results and constructive engagement with potential commercial partners, reflecting growing interest in new oral treatment options for prostate cancer. The amended agreement provides additional time for upcoming clinical data readouts and includes revised commercial terms, notably an increase in the number of consideration shares, highlighting the perceived value of the AO-252 asset.
More about Roquefort Therapeutics PLC
Roquefort Therapeutics PLC is a biotechnology company listed on the Main Market and focused on the development of novel cancer therapies. Its pipeline is centred on oral, targeted treatments for solid tumours, with a strategic focus on prostate cancer.
Leave a Reply